Our 5th Annual Neuroblastoma Parent Education Conference – ‘Understanding the Landscape of Neuroblastoma Research’ – was held at Latimer Place in Chesham.

This main aim of the conference was to inform parents and families on current and upcoming trials and research surrounding the disease affecting their children. Navigating the landscape can be overwhelming and this conference aimed to empower families to make informed decisions on behalf of their children.

We were joined by leading clinicians and researchers both from the UK and around the world. As well as a combination of presentations and open panels, the conference featured our Gala Dinner, which provided more opportunities for families and researchers to network and socialise in an informal setting.

We are very grateful to all the speakers who volunteered their time to attend the conference and for allowing us to share their presentations, which you can watch below.

Overview of high-risk neuroblastomaProfessor Deborah Tweddle, Great North Children’s Hospital, Newcastle upon Tyne

Overview of relapse treatment/refractory disease and BEACON/BEACON 2 - Dr Lucas Moreno, Hospital Niño Jesús, Madrid

Radionuclide Imaging & Therapy - Dr Mark Gaze, University College London Hospitals

ch14.18 + I/T + GM-CSF, COG - Dr Rajen Mody, C.S. Mott Children’s Hospital, Michigan

GPOH Research and perspectives - Professor Thorsten Simon, Children’s Hospital, University of Cologne

MSKCC, VACCINE, 3F8, hu3F8, NK Cells - Dr Shakeel Modak, Memorial Sloan-Kettering Cancer Centre, New York

Symptom management & care - Dr Anna-Karenia Anderson, The Royal Marsden Hospital & Shooting Star CHASE Hospices

Long-term follow-up care - Emma Potter, Clinical Nurse Specialist, the Royal Marsden Hospital

Post-Traumatic Stress – children and parents - Dr Anne Kazak, Nemours/Alfred l. DuPont Hospital for Children

SIOPEN HR-NBL1, VERITAS - Dr Guy Makin, Royal Manchester Children’s Hospital

Immunotherapy inc. INBRACED 2 – MIBG + ch14.18 + PD1 - Dr Juliet Gray, University Hospital Southampton

CAR T-CELL therapies - Professor John Anderson, Great Ormond Street Hospital

ALK, MYCN, PD(-L)1, eSMART - Professor Louis Chesler, The Institute of Cancer Research

Perspectives and future challenges - Dr Lucas Moreno on behalf of Professor Andy Pearson, formerly the Royal Marsden Hospital and the Institute of Cancer Research